Employees: 2,946
Size Maccura Biotechnology (300463.SZ) is a China Health Care company (Medical Specialties) with a market value of $756M, the 2709th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥8.45 on 18 Nov 2026.
Performance Over six months the shares fell 18.3%, against -13.5% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue fell 1.3% over the last twelve months (peer median +12.6%); the operating margin is -3.6% (peer median 12.8%).
Valuation It trades at 421.0× forward earnings against a peer median of 20.0× (most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 8% a year for seven years (Req g). Recent delivered growth is -10%, so the hurdle is +18 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.4 points below its cost of capital (6.3% WACC).
Next results Next results expected around 27 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.18B | CN¥2.15B | CN¥2.53B | CN¥2.88B | CN¥3.59B |
| Revenue growth | — | -15% | -12% | -20% | — |
| Gross profit | CN¥1.35B | CN¥925M | CN¥1.10B | CN¥1.31B | CN¥1.71B |
| EBITDA | n/a | CN¥338M | CN¥584M | CN¥636M | CN¥1.09B |
| Net income | -CN¥32.9M | -CN¥35.8M | CN¥127M | CN¥313M | CN¥708M |
| Free cash flow | CN¥208M | -CN¥147M | -CN¥326M | CN¥34.2M | -CN¥133M |
| Capital expenditure | CN¥562M | CN¥749M | CN¥963M | CN¥878M | CN¥988M |
| Total debt | CN¥842M | CN¥977M | CN¥789M | CN¥746M | CN¥703M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300463.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.2% | -7.1% | 11th highest of 21 |
| 6-month return | -18.3% | -13.5% | 9th lowest of 21 |
| Distance from 52-week high | -40.5% | -39.9% | 11th highest of 21 |
| Revenue growth (TTM) | -1.3% | +12.6% | 3rd lowest of 21 |
| Operating margin | -3.6% | 12.8% | 4th lowest of 21 |
| Forward P/E | 421.0× | 20.0× | most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 7.9% | 9.6% | 7th least demanding of 14 |
| Growth delivered (Del g) | -10.2% | +15.5% | 2nd lowest of 14 |
| Hurdle (Req g minus delivered) | +18.1 pp | -7.2 pp | 2nd most demanding of 14 |
| ROIC minus cost of capital | -3.4 pp | -0.3 pp | 7th lowest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | n/a | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 16.2× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 20.5× | 20.3% | -0.2% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 9.8× | -10.8% | +12.4% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | n/a | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 18.7× | -1.5% | +15.6% |
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $736M | -37% | +39% | 24% | 27.4× | 17.1% | +24.2% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Caina Technology 301122.SZ | China | $721M | +36% | +61% | 0% | 55.4× | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $710M | -22% | +6% | 14% | 22.8× | -3.4% | +15.7% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| SWS Hemodialysis Care 688410.SS | China | $706M | -11% | +31% | 19% | 23.5× | 16.2% | +25.9% |